Related Experiment Video
Updated: Feb 2, 2026

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells
Published on: February 4, 2021
LATS1 and LATS2 suppress breast cancer progression by maintaining cell identity and metabolic state
Noa Furth1, Ioannis S Pateras2, Ron Rotkopf3
1Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
Abstract:
Deregulated activity of LArge Tumor Suppressor (LATS) tumor suppressors has broad implications on cellular and tissue homeostasis. We examined the consequences of down-regulation of either LATS1 or LATS2 in breast cancer. Consistent with their proposed tumor suppressive roles, expression of both paralogs was significantly down-regulated in human breast cancer, and loss of either paralog accelerated mammary tumorigenesis in mice. However, each paralog had a distinct impact on breast cancer. Thus, LATS2 depletion in luminal B tumors resulted in metabolic rewiring, with increased glycolysis and reduced peroxisome proliferator-activated receptor γ (PPARγ) signaling. Furthermore, pharmacological activation of PPARγ elicited LATS2-dependent death in luminal B-derived cells. In contrast, LATS1 depletion augmented cancer cell plasticity, skewing luminal B tumors towards increased expression of basal-like features, in association with increased resistance to hormone therapy. Hence, these two closely related paralogs play distinct roles in protection against breast cancer; tumors with reduced expression of either LATS1 or LATS2 may rewire signaling networks differently and thus respond differently to anticancer treatments.
Insights
Large Tumor Suppressor (LATS) paralogs LATS1 and LATS2 have distinct roles in breast cancer. Loss of LATS2 alters metabolism, while LATS1 loss increases cancer cell plasticity and hormone therapy resistance.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Large Tumor Suppressor (LATS) proteins are critical for maintaining cellular and tissue homeostasis.
- Deregulated LATS activity is implicated in various cancers, including breast cancer.
- LATS1 and LATS2 are closely related paralogs with potentially distinct functions.
Purpose of the Study:
- To investigate the specific roles of LATS1 and LATS2 down-regulation in breast cancer.
- To understand the distinct molecular and cellular consequences of losing either LATS1 or LATS2 in breast cancer.
- To explore potential therapeutic vulnerabilities associated with LATS paralog loss.
Main Methods:
- Analysis of LATS1 and LATS2 expression in human breast cancer samples.
- Utilizing mouse models to study the impact of LATS1 or LATS2 depletion on mammary tumorigenesis.
- Investigating metabolic changes, signaling pathway alterations (e.g., PPARγ), and cellular plasticity upon LATS paralog loss.
- Assessing response to hormone therapy in LATS-depleted breast cancer models.
Main Results:
- Both LATS1 and LATS2 expression are significantly down-regulated in human breast cancer.
- Loss of either LATS1 or LATS2 accelerates mammary tumor development in mice.
- LATS2 depletion in luminal B tumors leads to metabolic rewiring (increased glycolysis, reduced PPARγ signaling) and sensitivity to PPARγ activation.
- LATS1 depletion promotes cancer cell plasticity, basal-like features, and resistance to hormone therapy in luminal B tumors.
Conclusions:
- LATS1 and LATS2 play distinct, non-redundant roles in suppressing breast cancer.
- Loss of LATS2 impacts tumor metabolism and offers a potential therapeutic target via PPARγ.
- Loss of LATS1 contributes to tumor dedifferentiation and endocrine therapy resistance.
- Understanding the differential roles of LATS paralogs is crucial for developing targeted breast cancer therapies.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
What is Metabolism?
Personal Identity
Trigonometric Identities II
Social Identity
Trigonometric Identities I

